In children with newly diagnosed high-risk B-cell ALL, replacing two chemotherapy cycles with blinatumomab improved estimated 4-year event-free survival (83.0% vs 70.3%; HR 0.51) at planned interim analysis, with less infection but more neurotoxicity.
RCTn = 709
Schrappe et al. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia